347 related articles for article (PubMed ID: 26957560)
1. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
Mao Y; Eissler N; Blanc KL; Johnsen JI; Kogner P; Kiessling R
Clin Cancer Res; 2016 Aug; 22(15):3849-59. PubMed ID: 26957560
[TBL] [Abstract][Full Text] [Related]
2. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.
Webb MW; Sun J; Sheard MA; Liu WY; Wu HW; Jackson JR; Malvar J; Sposto R; Daniel D; Seeger RC
Int J Cancer; 2018 Sep; 143(6):1483-1493. PubMed ID: 29665011
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
[TBL] [Abstract][Full Text] [Related]
4. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.
Davis RJ; Moore EC; Clavijo PE; Friedman J; Cash H; Chen Z; Silvin C; Van Waes C; Allen C
Cancer Res; 2017 May; 77(10):2607-2619. PubMed ID: 28364000
[TBL] [Abstract][Full Text] [Related]
6. Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.
Eissler N; Mao Y; Brodin D; Reuterswärd P; Andersson Svahn H; Johnsen JI; Kiessling R; Kogner P
Oncoimmunology; 2016; 5(12):e1232222. PubMed ID: 28123870
[TBL] [Abstract][Full Text] [Related]
7. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
[TBL] [Abstract][Full Text] [Related]
8. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
[No Abstract] [Full Text] [Related]
10. Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.
Allard B; Allard D; Stagg J
Methods Mol Biol; 2016; 1458():159-77. PubMed ID: 27581021
[TBL] [Abstract][Full Text] [Related]
11. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
12. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
13. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes.
Casacuberta-Serra S; Parés M; Golbano A; Coves E; Espejo C; Barquinero J
Immunol Cell Biol; 2017 Jul; 95(6):538-548. PubMed ID: 28108746
[TBL] [Abstract][Full Text] [Related]
15. CSF-1 maintains pathogenic but not homeostatic myeloid cells in the central nervous system during autoimmune neuroinflammation.
Hwang D; Seyedsadr MS; Ishikawa LLW; Boehm A; Sahin Z; Casella G; Jang S; Gonzalez MV; Garifallou JP; Hakonarson H; Zhang W; Xiao D; Rostami A; Zhang GX; Ciric B
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2111804119. PubMed ID: 35353625
[TBL] [Abstract][Full Text] [Related]
16. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
[TBL] [Abstract][Full Text] [Related]
17. Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells.
Santilli G; Piotrowska I; Cantilena S; Chayka O; D'Alicarnasso M; Morgenstern DA; Himoudi N; Pearson K; Anderson J; Thrasher AJ; Sala A
Clin Cancer Res; 2013 Mar; 19(5):1116-25. PubMed ID: 23322899
[TBL] [Abstract][Full Text] [Related]
18. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.
Tao H; Liu M; Wang Y; Luo S; Xu Y; Ye B; Zheng L; Meng K; Li L
Front Immunol; 2021; 12():609295. PubMed ID: 33717093
[TBL] [Abstract][Full Text] [Related]
19. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
20. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
